Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In the double-blind Phase IIIb EXCEEDS trial in about 200 patients, treatment with Xyrem alone or in combination
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury